 "Lupin Pharma")
Lupin has moved higher by 9% to Rs 1,698 on the National Stock Exchange (NSE) after the pharma major announced on Thursday that US Food and Drug Administration (USFDA) has issued an Establishment Inspection Reports (EIR) for its Goa facility.
“The company has received notification that the inspection carried out by the US FDA in July 2015 at its Goa facility is now closed and the agency has issued an Establishment Inspection Reports (EIR),” Lupin said in a press release.
“The company has received notification that the inspection carried out by the US FDA in July 2015 at its Goa facility is now closed and the agency has issued an Establishment Inspection Reports (EIR),” Lupin said in a press release.
However, the responses from the March 2016 US FDA inspection and updates thereafter are still under review by the agency, it added.
At 03:27 PM, the stock was up 8% at Rs 1,691 on the NSE, as compared to 0.06% rise in the Nifty 50. A combined 3.24 million shares changed hands on the counter on the NSE and BSE so far.
